Obituary: Professor Caroline Ogilvie OBE

When I arrived at King's College London in August 2009, Professor Peter Braude introduced me to Caroline Ogilvie with words I have never forgotten. She was, he said, one of the sharpest minds he had encountered during his career. Before submitting a paper or grant application, I should give it to Caroline: she would find its weaknesses before any reviewer did.

Peter was right. Caroline had an extraordinary ability to see what others had missed. It did not matter if the subject lay outside her own field. She would identify the unresolved question, unsupported conclusion or practical obstacle that everyone else had overlooked. Her thinking was rigorous and unsentimental, but never narrow. She combined intellectual precision with curiosity, imagination and an instinctive understanding of how science could be translated into something genuinely useful.

Over the years, Caroline became much more than a colleague and collaborator. She became my dear friend. We shared an interest in preimplantation embryos and early human development, worked together on numerous projects and co-authored more than a dozen papers. I relied on her judgment, but also treasured our conversations. Even after decades in science, Caroline retained an infectious enthusiasm for a new idea, an unexpected result or a technology that might improve patients' lives.

Caroline was a giant in clinical cytogenetics. During a career spanning approximately half a century, she helped transform the diagnosis of genetic disorders in the UK. She understood emerging technologies in unusual depth but was never interested in novelty for its own sake. Her questions were always practical: Would this give patients a better answer? Could it be introduced safely into clinical practice? Could it be made faster, more reliable and more affordable for the NHS?

In the 1990s, she helped introduce fluorescence in situ hybridisation into the clinical service at Guy's Hospital, London, to detect chromosome changes too small to be seen by conventional methods. She subsequently spearheaded the development of quantitative fluorescence PCR for the rapid prenatal diagnosis of common chromosomal conditions, including Down's syndrome. This shortened the agonising wait for families from around two weeks to a matter of days and helped provide a model for services established across the country.

Caroline was also pivotal in bringing on-screen karyotyping to Guy's, replacing laborious microscope-based analysis. Characteristically, she later helped make that advance largely obsolete by driving the implementation of array comparative genomic hybridisation, which provided higher-resolution testing and improved the likelihood of reaching a diagnosis. Under her influence, the Guy's service grew into one of the highest-throughput array services in the UK.

She also developed cost-effective approaches to analysing pregnancy losses, combining molecular techniques to maximise the detection of chromosomal abnormalities while avoiding slow and expensive cell culture. Caroline had no attachment to a technique simply because it was familiar or because she had helped introduce it. If something better became possible, she wanted patients to benefit from it.

Her contribution to reproductive genetics was particularly important. Through her close relationship with the Assisted Conception Unit at Guy's, Caroline helped establish a national preimplantation genetic diagnosis service for couples carrying chromosome rearrangements. This offered an alternative to repeated miscarriage or the painful prospect of terminating an affected pregnancy. She also helped develop preimplantation genetic haplotyping, which greatly widened access to testing for families at risk of inherited single-gene disorders.

Behind these technical terms were real families. Caroline never lost sight of that. Her office was filled with photographs, letters and cards from parents whose children had been born following treatment made possible by her work. They were perhaps the clearest measure of her achievement. Thousands of patients benefited from technologies that she had evaluated, refined and helped move from research into routine clinical care.

Caroline's influence extended well beyond her laboratory. Her expertise was sought by the Human Fertilisation and Embryology Authority, including in its evaluation of techniques intended to prevent the transmission of mitochondrial disease. She published more than 200 scientific papers and mentored generations of clinical scientists, particularly women as they progressed into senior roles. Colleagues trusted her because she was rigorous, independent and courageous enough to say what she genuinely thought.

After formally retiring, Caroline continued to support the diagnostic service in an almost full-time voluntary capacity for several years. Science was not simply her profession; it was part of who she was. Her contribution was recognised nationally when she was appointed OBE in the 2025 King's Birthday Honours for services to patients with genetic disorders (see BioNews 1294). It was an honour she richly deserved.

Yet a list of innovations, papers and honours cannot fully capture Caroline. Those fortunate enough to know her will remember her formidable clarity of thought and refusal to accept an easy answer when a better one could be found. We will also remember her loyalty, generosity and willingness to give her time and intellect to other people's work. She could be direct, but her directness came from honesty and a desire to make the science stronger. If Caroline believed in you or in an idea, her support was steadfast.

Caroline once said something that has remained with me: life consists of an endless succession of choices. We make many of them every day, sometimes without recognising their importance, and together those choices make us who we are. Her own life gave those words particular force. Again and again, Caroline chose intellectual honesty over convenience, action over complacency, and service to patients over personal recognition.

For me, the loss is deeply personal. I have lost a trusted collaborator, an intellectual companion and a dear friend. I will miss taking a new idea to Caroline, knowing that she would test it mercilessly, improve it immeasurably and then become as excited as anyone about what it might achieve.

Caroline changed clinical genetics, but, more importantly, she changed the lives of patients and families. Her work lives on in the services she helped create, the scientists she mentored and the children whose births were made possible by her knowledge and determination. The choices she made shaped not only who she was, but also the lives of countless others. We owe her an enormous debt, and we will miss her greatly.